Synthesis and receptor binding affinity of carboxylate analogues of the mannose 6-phosphate recognition marker.

Audrey Jeanjean, Marcel Mg Garcia, Alain Leydet, Jean-Louis Montero,
Alain Morère

► To cite this version:

Audrey Jeanjean, Marcel Mg Garcia, Alain Leydet, Jean-Louis Montero, Alain Morère. Synthesis and receptor binding affinity of carboxylate analogues of the mannose 6-phosphate recognition marker.. Bioorganic and Medicinal Chemistry, 2006, 14 (10), pp.3575-82. 10.1016/j.bmc.2006.01.024 . inserm-00144764

HAL Id: inserm-00144764

<https://www.hal.inserm.fr/inserm-00144764>

Submitted on 7 May 2007

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Synthesis and receptor binding affinity of carboxylate analogues of the Mannose 6-Phosphate recognition marker

Audrey Jeanjean,^a Marcel Garcia,^b Alain Leydet,^a Jean-Louis Montero,^a and Alain Morère^{a,*}

^a Laboratoire de Chimie Biomoléculaire, Université Montpellier II

Ecole Nationale Supérieure de Chimie de Montpellier, 8 Rue de l'Ecole Normale

F-34296 Montpellier Cedex 05, France

E-mail : morere@univ-montp2.fr

Tel : Int +33 4 67 14 43 45

Fax : Int +33 4 67 14 43 44

^b INSERM, Unité 540, EMCC, 60 Rue de Navacelles, F-34090 Montpellier, France

Abstract :

The mannose 6-phosphate/ insulin-like growth factor II receptor (M6P/IGF2R) is involved in multiple physiological pathways including targeting of lysosomal enzymes, degradation of IGF2 and cicatrisation through TGF β activation. To target potential therapeutics to this membrane receptor, four carboxylate analogues of mannose 6-phosphate (M6P) were synthesized. Three of them, two isosteric carboxylate analogues and a malonate derivative, showed a binding affinity for the M6P/IGF2R equivalent or higher than that of M6P. On the contrary to M6P, all these analogues were particularly stable in human serum. Moreover, these derivatives did not present any cytotoxic activity against two human cell lines. These analogues represent a new potential for the lysosomal targeting of enzyme replacement therapy in lysosomal diseases or to prevent the membrane-associated activities of the M6P/IGF2R.

1. Introduction

The mannose 6-phosphate (M6P) is a recognition marker involved in the selective targeting of newly synthesized lysosomal enzymes from the *trans*-Golgi network (TGN) to endosomes. Sorting and transport of lysosomal enzymes are ensured by two receptors, the 46 kDa cation dependent-M6P receptor (CD-M6PR) and the 300 kDa cation independent-M6P receptor (CI-M6PR). After releasing of enzymes, the receptors are recycled back to the Golgi apparatus or move to the plasma membrane, where the CI-M6PR internalizes exogenous lysosomal enzymes while CD-M6PR is unable to endocytose hydrolases.¹ In addition to its ability to recognize M6P-containing proteins, the CI-M6PR is implicated in many other physiological processes. CI-M6PR is known as M6P/IGF2R since it binds the non-glycosylated insulin-like growth factor II (IGF2) at the cell surface. Binding of this growth factor is followed by internalization and subsequent degradation in the lysosomes.² The M6P/IGF2R also binds retinoic acid (RA) with high affinity at a binding site that is different from those for IGF2 and M6P on the receptor.³ In addition to lysosomal enzymes, the M6P/IGF2R binds other M6P-containing proteins, including for instance the Granzyme B,⁴ which is a protease involved in cytotoxic-T-cell-induced apoptosis, or the latent transforming growth factor- β (LTGF- β) complex, which is activated at the surface of the receptor.⁵ Moreover, several clinical studies indicated that the M6P/IGF2R could act as a tumour suppressor. Indeed, overexpression of the receptor acts as a growth inhibitor⁶ while loss of receptor function is associated with progression of tumorigenesis.⁷

In the laboratory we focused on the M6P/IGF2R ability to bind extracellular M6P-bearing ligands in the hypothesis to use this receptor as a therapeutic target. To better understand the molecular basis for the interaction of the M6P/IGF2R with M6P, we synthesized several carboxylate and malonate analogues of M6P and we studied their binding affinities for the M6P/IGF2R. In an attempt to use these synthetic analogues in therapeutical approaches we also evaluate their stability in serum and their cytotoxicity in human cells.

2. Results and discussion

The M6P/IGF2R is a type I transmembrane glycoprotein which possesses four structural domains: an amino-terminal signal sequence, an extracytoplasmic region which contains the different binding sites, a transmembrane region and a carboxyl-terminal cytoplasmic domain. The large extracellular domain has a structure consisting of 15 contiguous repeating domains. The sequence homology between the 15 repeating segments suggests that the M6P/IGF2R

could contain 15 M6P binding sites. In fact, experiments revealed that the M6P/IGF2R binds only 2 mol of M6P.⁸ The presence of two different carbohydrate recognition domains in the M6P/IGF2R provides this receptor with a functional advantage over the CD-M6PR, which contains only one. This difference certainly explains why the M6P/IGF2R recognizes a wider spectrum of lysosomal enzymes than does the CD-M6PR.^{9,10} For instance, the M6P/IGF2R, unlike the CD-M6PR, binds very efficiently *Dictyostelium discoideum* lysosomal enzymes, which contain in their structure the phosphodiester Man-P-OCH₃¹¹ and the mannose 6-sulfate (M6S)¹². These findings are particularly interesting because they demonstrate that a single negative charge on the phosphate moiety, as well as on the sulfate group, is sufficient to preserve the recognition phenomenon by the M6P/IGF2R. Another structural factor, which contributes in the binding to the M6P/IGF2R, is the axial 2-hydroxyl group in the M6P. Indeed, glucose 6-phosphate, the 2-epimer of M6P, is a poor inhibitor for the M6P/IGF2R.¹³ On the other hand, the hydroxyl group at the anomeric position of M6P appears to be unimportant in the binding to the receptor.¹³

As a single negative charge on the M6P is sufficient to preserve the recognition phenomenon we decided to synthesize a series of isosteric or non isosteric carboxylate analogues of M6P to determine their binding affinities for the M6P/IGF2R.

2.1 Synthesis of carboxylate analogues of M6P

Two isosteric carboxylate analogues of M6P were prepared with slight modifications to the synthesis protocols previously reported.¹⁴ The new synthesis of these carboxylates began with the selective oxidation¹⁵ of the methyl 2,3,4,6-tetra-*O*-trimethylsilyl- α -D-mannopyranoside¹⁶ using the Collins oxidative reagent (CrO₃-pyridine), scheme 1. In this procedure, there are selective trimethylsilyl ether removal at 6-position and concomitantly oxidation of the intermediate alcohol to aldehyde.¹⁵ To the aldehyde, obtained in this one step procedure, was added the anion of triethyl phosphonoacetate to lead to the carboxylate **1** in 51%. Synthetic intermediate **1** was readily converted to the desired deprotected carboxylate **2** by desilylation at 2,3,4-positions using the ceric ammonium nitrate (CAN) then saponification (NaOH) of the ester moiety. The saturated carboxylate **3** was obtained by catalytic hydrogenation of a fraction of **2**.

Scheme 1. Reagents and conditions : (i) $\text{CrO}_3/\text{pyridine}$, CH_2Cl_2 , 0°C , 1 h; (ii) $(\text{EtO})_2(\text{O})\text{P}-\text{CH}_2-\text{CO}_2\text{Et}$, NaH , THF , 10 min; (iii) CAN , $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ (95/5), 15 min; (iv) 2 N NaOH , 1 h; (v) $\text{H}_2/\text{Pd/C}$, EtOH , 4 h.

The carboxylate **6**, non isosteric analogue of M6P, was synthesized according to scheme 2. The anion of the methyl 2,3,4-tri-*O*-benzyl- α -D-mannopyranoside¹⁷ reacted with the *tert*-butyl bromoacetate through a $\text{S}_{\text{N}}2$ mechanism and the compound **4** was prepared in 74% yield in this manner. The target product **6** was obtained after deprotection of the carboxylate moiety (**5**) followed by the removal of the benzyl protective groups. It is to note that assays of reaction of the anion of the methyl 2,3,4-tri-*O*-benzyl- α -D-mannopyranoside on the less hindered ethyl or methyl bromoacetates failed to give cleanly the ether oxide function at 6-position since many by-products were observed.

Scheme 2. Reagents and conditions : (i) NaH, DMF, 30 min, then tBuO₂C-CH₂Br, 3 h; (ii) TFA, Et₃SiH, CH₂Cl₂, 15 h, then DOWEX Na⁺; (iii) H₂/Pd/C, EtOH, 4 h.

2.2. Synthesis of a mannose 6-malonate derivative.

The key step for the synthesis of the malonate **9**, scheme 3, was the reaction of the anion of dimethyl malonate with the methyl 2,3,4-tri-*O*-benzyl-6-*O*-trifluoromethylsulfonyl- α -D-mannopyranoside¹⁸ while the less reactive tosylate or mesylate at C-6 of the methyl 2,3,4-tri-*O*-benzyl- α -D-mannopyranoside were not displaced under the same conditions of reaction. The malonate **7**, thus obtained, underwent saponification (**8**) and subsequent hydrogenation to afford the desired product **9**.

Scheme 3. Reagents and conditions: (i) (MeO₂C)₂CHNa, THF, 15 h reflux; (ii) 4 N NaOH, THF/H₂O (4/6), 35 min), then 5 N HCl; (iii) 1. H₂/Pd/C, EtOH/AcOEt (7/3), 4 h, then DOWEX Na⁺.

2.3 Biological evaluation

The binding assays of the M6P analogues were performed using biotinylated M6P/IGF2R (M6P/IGF2R_b). Briefly, the M6P/IGF2R, purified on a phosphomannan-sepharose affinity column¹⁹, was biotinylated²⁰ by N-hydroxysuccinimid biotin. The binding of the M6P/IGF2R_b to pentamannose 6-phosphate (PMP) previously adsorbed to a microtiter plate, was displaced by increasing concentrations of the analogues. The bound M6P/IGF2R_b was then determined using the couple streptavidin/peroxidase and OPD substrate by optical densities measurements as described in Experimental procedures. In preliminary experiments the method was standardized by the determination of the maximal concentration of PMP adsorbed to the microtiter plate and to the M6P/IGF2R_b concentration required to saturate the adsorbed PMP (Figure 1).

Figure 1. Determination of PMP adsorption in microtiter wells and M6P/IGF2Rb binding. A. The binding of 2.5 µg.mL⁻¹ M6P/IGF2Rb to increasing concentrations of PMP adsorbed on microtiter plate was evaluated using the streptavidine/peroxidase procedure. B. The retention of various concentrations of M6P/IGF2Rb (0 to 5 µg.mL⁻¹) to the microplate previously saturated with 100 µg.mL⁻¹ PMP was determined after overnight incubation at 4 °C.

From these measurements of the receptor binding in the presence of increasing concentrations of analogues **2**, **3**, **6** or **9**, were drawn dose-inhibition curves (Figure 2) from which were determined the IC₅₀ values reported in table 1.

Figure 2. Displacement of PMP from M6P/IGF2Rb by M6P analogues.

First analysis of the data given in table 1 shows that M6P presents IC_{50} values in good accordance with those reported in the literature.²¹

Table 1. Binding affinities for M6P/IGF2R.

Compound	IC_{50} (M)	RBA	Compound	IC_{50} (M)	RBA
M6P	$2.3 \cdot 10^{-5} \pm 1 \cdot 10^{-5}$	1.0	PMP	$5.6 \cdot 10^{-6} \pm 0.7 \cdot 10^{-6}$	4.1
2	$3.9 \cdot 10^{-5} \pm 1.1 \cdot 10^{-5}$	0.6	6	$> 1 \cdot 10^{-3}$	na*
3	$7.4 \cdot 10^{-5} \pm 1.9 \cdot 10^{-5}$	0.3	9	$1.2 \cdot 10^{-5} \pm 0.3 \cdot 10^{-5}$	1.9

Relative Binding Affinity = RBA = $IC_{50} \text{ (M6P)} / IC_{50} \text{ (Analogue)}$. * na = not applicable.

The unsaturated isosteric analogue **2** binds to M6P/IGF2Rb as well as M6P while the saturated isosteric analogue **3** binds to the receptor with a slightly weaker affinity than does M6P. This is a confirmation of the results previously obtained by elution of the receptor from PMP affinity columns.¹⁴ Indeed, it was demonstrated that 2.5 mM of the conjugated derivative **2** eluted the M6P/IGF2R, retained on phophomannan sepharose column, as the M6P whereas **3** allowed the elution of the receptor at a higher concentration (5 mM). To explain this difference in binding affinity, it is presumed that the geometry of the double bond

in **2** leads to greater interaction with the M6P-binding sites of the M6P/IGF2R, in comparison with the single bond in **3**. On the other hand, the non isosteric derivative **6** is weakly recognized by the M6P/IGF2Rb. We suppose that **6** does not match exactly the M6P-binding sites of the receptor because the distance between the negative charge and the pyranose ring in **6** is not in the same range as that in the M6P. Indeed, this distance in **6**, by comparison to the isosteric M6P analogue **3**, is lengthened by an oxygen atom in the middle of the lateral carbon chain and this lengthening of the lateral chain probably impairs the binding affinity. A high binding affinity was obtained with the malonate **9** which is as well recognized by the M6P/IGF2Rb as the M6P itself. This last result does not correlate exactly with IC₅₀ values determined by Berkowitz *et al.*²¹ However, their binding test followed a procedure in which the M6P/IGF2R was covalently bound to a Sepharose resin, while in our case the M6P/IGF2Rb was not bound to a support. This difference could perhaps explain the differences observed between the binding affinities.

The stability after a 2 day-incubation in human serum at 37 °C of the analogues **2**, **3** and **9** was compared to M6P. Figure 3 showed that the analogues **2**, **3** and **9** were recognized similarly along time, while M6P shown a decreased affinity for the receptor after 2 day-incubation in serum. Moreover, a 6h-incubation appeared sufficient to decrease the binding of M6P by 32% (Figure 3 insert). This indicates that, in opposite to M6P which is rapidly degraded by hydrolases, and particularly phosphatases, all the analogues tested are stable after a long exposure in human serum.

Figure 3: Stability of the analogues in human serum.

The binding of M6P/IGF2R to PMP was measured in the absence (control) or in the presence of the analogues as described in Experimental procedures. The competition by the analogues was performed in the absence or presence of serum either directly (0 day + serum) or after incubation for 2 days at 37 °C. The insert indicates the competition by 5 10⁻⁴ M M6P incubated for the indicated times at 37 °C in the presence of human serum.

Moreover, we evaluated the cytotoxicity of the analogues **2**, **3** and **9** on MCF7 or MDA-MB-231 human breast cancer cell lines (Figure 4). After 4 days in the culture medium, all the compounds appeared non cytotoxic even at high concentration (10⁻⁴ M) on these two cell lines.

Figure 4. Absence of cytotoxicity of the analogues in human cell lines. MDA-MB-231 and MCF7 cells were grown for 4 days in the presence of the indicated concentrations of analogues and the cell growth was evaluated in triplicate as described in Experimental procedures. Standard deviations of the means were always inferior to 5%.

3. Conclusion

This study underlines the fact that a single negative charge on an isosteric analogue derivative of M6P is sufficient to preserve the recognition by the M6P/IGF2R. The affinity of the conjugated analogue **2** was in the same order than for M6P, while the saturated derivative **3** was slightly less well recognized by the M6P/IGF2R. Similarly to M6P, the malonate **9** can exist under a dianionic state at physiological pH. This could explain the very good affinity of **9** for the receptor. Moreover, the two carboxylic acid functions at the terminal carbon chain of **9** did not seem to impair the recognition phenomenon by steric hindrance.

Therefore compounds **2**, **3** and **9** that present very good affinities for M6P/IGF2R could be good candidates for the treatment of various diseases. For instance, they could be used to improve wound healing which is known to be favoured by M6P delivery on the site of wounds.²² Another application could be in enzyme replacement therapy, especially in lysosomal diseases. In fact the source for recombinant enzyme synthesis is restricted to mammalian cells by the fact that other organisms do not possess the M6P recognition pathway. The coupling of stable M6P analogues could permit the use of other sources of recombinant enzyme such as bacteria or insect cells and to increase the targeting efficiency of the infused enzymes to tissues enriched in M6P receptors.

4. Experimental procedures

4.1. General Aspects: All solvents were dried prior to use according to standard methods.²³ – Analytical TLC were performed using aluminum-coated TLC plates 60-F₂₅₄ (Merck). – Plates were developed with (1) UV light (254 nm), and (2) immersion in a 10% H₂SO₄/EtOH solution – Silica gel column chromatography was performed with silica gel 60A (Carlo Erba). – Optical rotations were measured at the sodium D-line with a Perkin-Elmer-241 polarimeter. –Electron ionization mass spectra (30 eV) were recorded in positive or negative mode on a Waters MicroMass ZQ – ¹H NMR Spectra were recorded on a Brüker DRX 400 (400 MHz), at 25 °C. Chemical shifts (δ) are given in ppm and referenced using residual solvent signals (7.24 ppm for CHCl₃ and 4.79 ppm for HOD). The following abbreviations were used to explain the signal multiplicities or characteristics: s (singlet), d (doublet), dd (double doublet), ddd (double double doublet), t (triplet), td (triplet doublet), q (quartet), m (multiplet). – ¹³C NMR Spectra were recorded on a Brüker DRX 400 (100.6 MHz). Chemical shifts (δ) are given in ppm relative to TMS as an external reference. – The pentamannose 6-phosphate (PMP) was functionalized with β-(*p*-aminophenyl)ethylamine, then reduced with sodium tetrahydroborate, and finally coupled on CNBr activated Sepharose leading to phosphomannan Sepharose.²⁴ – Buffers and solutions used in the purification of M6P/IGF2R and in the ELISA assays were : buffer A (50 mM imidazol pH 7 ; 150 mM NaCl ; 5 mM β-glycerophosphate ; 0.05% Triton x-100 (w/v)); PBS (1.9 mM NaH₂PO₄, 8.1 mM Na₂PO₄ and 154 mM NaCl, pH 7.4); carbonate buffer (0.1M NaHCO₃/Na₂CO₃, pH 9.6); washing buffer (2 mg.mL⁻¹ gelatine in PBS); OPD (o-phenylenediamine 1mg.mL⁻¹ in citrate buffer pH 5.0 and 1 μL 30% H₂O₂.)

4.2. Ethyl (methyl (E)-6,7-dideoxy-2,3,4-tri-*O*-trimethylsilyl-α-D-manno-oct-6-enopyranosid)uronate 1

Finely ground and thoroughly dried chromium (VI) oxide (2.5 g, 24.88 mmol) were suspended in dry dichloromethane (80 mL) containing dry pyridine (4 mL). The mixture was stirred at room temperature for 30 min. Then, the mixture was cooled at 0 °C and methyl 2,3,4,6-tetra-*O*-trimethylsilyl-α-D-mannopyranoside¹⁶ (2 g, 4.15 mmol) dissolved in dry dichloromethane (6 mL) was added. After 1 h the mixture was filtered over silica gel to

remove insoluble chromium compounds. The filtrate was concentrated in vacuo affording the aldehyde (1.24 g, 73%) that was used for the next step without further purification.

To a suspension of NaH (98%, 204 mg, 8.33 mmol) in THF (2 mL) was added triethyl phosphonoacetate (2 mL, 9.99 mmol). Reaction was stirred for 30 min at room temperature, then a solution of the crude aldehyde in THF (10 mL) was added dropwise. The reaction was monitored by TLC (light petroleum/Et₂O 9/1 v/v) and stirred for 10 min before concentrating under reduced pressure. The residue was diluted with CH₂Cl₂ and the organic layer washed with brine, dried (Na₂SO₄), filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (light petroleum/Et₂O 95/5 then 9/1 v/v) to afford **1** (1.4 g, 70%) as a yellow oil. The spectroscopic data were in accordance with literature.¹⁴

4.3. Sodium (methyl (E)-6,7-dideoxy- α -D-manno-oct-6-enopyranosid)uronate **2**

CAN (298 mg, 0.54 mmol) was added to a solution of **1** (1.3 g, 2.72 mmol) dissolved in a mixture of (CH₃CN/H₂O 95/5 v/v, 15 mL). The reaction was monitored by TLC (AcOEt/MeOH 92/8 v/v). After 20 min stirring at room temperature, the mixture was diluted with CH₂Cl₂. The organic layer was washed with H₂O, brine, dried (Na₂SO₄), filtered and concentrated under reduced pressure. Ethyl (methyl (E)-6,7-dideoxy- α -D-manno-oct-6-enopyranoside)uronate (712 mg, quantitative) was obtained pure as a colorless oil. The spectroscopic data were in accordance with literature.¹⁴

Ethyl (methyl (E)-6,7-dideoxy- α -D-manno-oct-6-enopyranosid)uronate (700 mg, 2.67 mmol) was dissolved in 2 N NaOH (20 mL) at 0 °C. The mixture was stirred for 1 h and neutralized with 0.5 N HCl until pH 7. Then, ion exchange resin (Dowex 50WX2, Na⁺ form, 20 g) was added. After stirring at room temperature for 2 h, the resin was filtered off and washed with H₂O (100 mL). The filtrate was freeze dried from H₂O affording **2** (650 mg, 95%) as a white foam. The spectroscopic data were in accordance with literature.¹⁴

4.4. Sodium (methyl 6,7-dideoxy- α -D-manno-octopyranosid)uronate **3**

A solution of **2** (600 mg, 2.34 mmol) in EtOH (20 mL) was stirred vigorously under H_{2(g)} for 4 h in the presence of 10% Pd-C as catalyst. The mixture was filtered under celite, then

washed with EtOH (100 mL) and concentrated. The crude product was purified by column chromatography on RP-18 silica gel using water as eluent. After freeze drying, **3** (568 mg, 94%) was obtained as a white foam. The spectroscopic data were in accordance with literature.¹⁴

4.5. Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(2-*tert*-butoxy-2oxoethyl)- α -D-mannopyranoside **4**

To a solution of methyl 2,3,4-tri-*O*-benzyl- α -D-mannopyranoside¹⁷ (581 mg, 1.25 mmol) in dry DMF (5 mL), NaH (60%, 200 mg) was added under argon. The reaction was stirred at room temperature for 3 h. Then, *tert*-butyl bromoacetate (1.82 mL, 12.32 mmol) was added dropwise at room temperature and the mixture was stirred for 3 h. The solution was diluted with CH₂Cl₂ (100 mL) and the organic layer was washed with brine (100 mL), dried (Na₂SO₄), filtered, concentrated and purified by silica gel column chromatography (light petroleum/Et₂O 9/1 then 8/2 v/v) to give **4** (537 mg, 74%) as a colorless oil. *R*_f 0.55 (light petroleum/AcOEt 8/2). [α]_D²⁰ +29.36 (*c* 1.1 / CHCl₃). ¹H NMR (CDCl₃), δ : 1.32 (s, 9H, 3CH₃); 3.17 (s, 3H, OCH₃); 3.60 (m, 1H, H-5); 3.67 (d, 1H, *J*₂₋₃ = 2.3 Hz, H-2); 3.70 (d, 2H, *J*_{CH2-5} = 3.7 Hz, H-6 and 6'); 3.78 (dd, 1H, *J*₃₋₄ = 9.3 Hz, H-3); 3.83 (t, 1H, *J*₄₋₅ = 9.3 Hz, H-4); 3.93 (s, 2H, H-7 and 7'); 4.48-4.63 (m, 5H, CH₂Ph); 4.59 (s, 1H, H-1); 4.83 (d, 1H, *J*_{a-b} = 10.8 Hz, CH₂Ph); 7.10-7.24 (m, 15H, 15H-ar). ¹³C NMR (CDCl₃), δ : 28.32, 28.43, 28.55 (3CH₃); 55.18 (OCH₃); 69.72 (C-7); 70.99 (C-6); 72.20 (C-5); 72.54, 73.11 (2CH₂Ph); 74.98 (C-2); 75.20 (C-4); 75.43 (CH₂Ph); 80.63 (C-3); 81.75 (C(CH₃)₃); 99.44 (C-1); 127.94-128.75 (15CH-ar); 138.77, 138.98, 139.07 (3C^{IV}-aro); 170.05 (CO). MS ESI⁺, *m/z*: 601 [M+Na]⁺.

4.6. Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(carboxymethyl)- α -D-mannopyranoside sodium salt **5**

To a solution of **4** (532 mg, 0.92 mmol) and trifluoroacetic acid (918 μ L, 11.92 mmol) in CH₂Cl₂ (2 mL), triethylsilane (366 μ L, 2.29 mmol) was added under argon atmosphere. The reaction was stirred at room temperature for 15 h. After evaporation of solvents, the residue was dissolved with water (50 mL) and cation exchange resin in the Na⁺ form was added. After stirring at room temperature for 1 h, the resin was filtered off and washed several times with water. The aqueous phase was lyophilized to afford **5** (466 mg, 97%) as a white solid. *R*_f 0.13 (light petroleum /AcOEt 5/5). [α]_D²⁰ -2.99 (*c* 1.8 / CHCl₃). ¹H NMR (CDCl₃), δ : 3.13 (s, 3H, CH₃O); 3.40-3.54 (m, 3H, H-5, H-6 and 6'); 3.70 (dd, 1H, *J*₂₋₁ = 1.2 Hz, *J*₂₋₃ = 2.5 Hz, H-2); 3.62-3.73 (m, 2H, H-7 and 7'); 3.77 (dd, 1H, *J*₃₋₄ = 9.5 Hz, H-3); 3.97 (t, 1H, *J*₄₋₅ = 9.5 Hz, H-4); 4.48 (s, 2H, CH₂Ph); 4.53 (d, 1H, *J*_{a-b} = 11.5 Hz, CH₂Ph); 4.64 (d, 1H, H-1);

4.73 (d, 1H, $J_{a'-b'}$ = 12.8 Hz, CH_2Ph); 4.81 (d, 2H, $2CH_2Ph$); 7.14-7.29 (m, 15H, 15H-ar). ^{13}C NMR ($CDCl_3$), δ : 55.58 (OCH_3); 67.96 (C-7); 69.06 (C-6); 70.51 (C-5); 72.34 (C-2); 72.50 (CH_2Ph); 73.30 (C-4); 73.45 (CH_2Ph); 75.52 (CH_2Ph); 80.50 (C-3); 100.25 (C-1); 127.81-129.09 (15CH-aro); 137.54, 138.39, 138.56 ($3C^{IV}$ -aro); 176.08 (CO). MS ESI⁺, m/z : 545.15 $[M+H]^+$.

4.7. Methyl 6-*O*-(carboxymethyl)- α -D-mannopyranoside sodium salt 6

To a solution of **5** (87 mg, 0.17 mmol) in EtOH (5 mL) was added 150 mg of 10% Pd/C. After stirring under $H_{2(g)}$ for 4 h, the mixture was filtered through Celite pad, then washed with EtOH (100 mL) and concentrated under vacuum. The crude product was purified by column chromatography on reversed phase (RP-18, H_2O). After lyophilization, **6** was obtained as a white powder (37 mg, 88%). R_f 0.25 ($NH_4OH/H_2O/iPrOH$ 1/1/8). $[\alpha]_D^{20} +45.75$ (c 0.8 / D_2O). 1H NMR (D_2O), δ : 3.29 (s, 3H, OCH_3); 3.61-3.81 (m, 6H, H-2, 3, 4, 5, 6); 4.10 (s, 2H, CH_2O); 4.64 (s, 1H, H-1); ^{13}C NMR (D_2O), δ : 54.85 (OCH_3); 68.23 (C-7); 69.91 (C-6); 66.57, 69.82, 70.35, 71.13 (C-2,3,4,5); 100.94 (C-1); 175.72 (CO). MS ESI⁻, m/z : 251.20 $[M-Na]^+$.

4.8. Methyl (methyl 2,3,4-tri-*O*-benzyl-6,7-dideoxy-7-(methoxycarbonyl)- α -D-mannooctopyranosid)uronate 7

To a solution of dimethyl malonate (0.66 g, 5.0 mmol) in THF (15 mL), sodium hydride (0.1 g, 2.5 mmol) was added. The mixture was stirred under nitrogen for 30 min, then a solution of methyl 2,3,4-tri-*O*-benzyl-6-*O*-trifluoromethanesulfonyl- α -D-mannopyranoside¹⁸ (1.14 g, 1.92 mmol) in THF (4 mL) was added dropwise. The mixture was refluxed for 15 h, allowed to cool at room temperature, quenched with saturated ammonium chloride and extracted with ether. The organic layer was washed with brine, dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (light petroleum/Et₂O 8/2 then 7/3 v/v) affording **7** (722 mg, 65%) as a colorless oil. R_f 0.59 (Et₂O/light petroleum 6/4). $[\alpha]_D^{20} +36.4$ (c 1.29 / $CHCl_3$). 1H NMR ($CDCl_3$), δ : 2.04 (ddd, 1H, $J_{6'-5}$ = 9.9 Hz, $J_{6'-6}$ = 14.0 Hz, $J_{6'-7}$ = 4.7 Hz, H-6'); 2.50 (ddd, 1H, J_{6-5} = 2.4 Hz, J_{6-7} = 10.7 Hz, H-6); 3.19 (s, 3H, OCH_3); 3.47 (td, 1H, J_{5-4} = 9.9 Hz, H-5); 3.57-3.68 (m, 3H, H-2, 4 et 7); 3.63 et 3.64 (2s, 6H, $2OCH_3$); 3.76 (dd, 1H, J_{3-2} = 3.0 Hz, J_{3-4} = 9.6 Hz, H-3); 4.51 (s, 2H, CH_2Ph); 4.54 (d, 1H, J_{1-2} = 1.5 Hz, H-1); 4.58 (d, 1H, J_{a-b} = 10.9 Hz, CH_2Ph); 4.61 (d, 1H, $J_{a'}$

b' = 12.3 Hz, CH_2Ph); 4.67 (d, 1H, CH_2Ph); 4.86 (d, 1H, CH_2Ph); 7.18-7.29 (m, 15H, 15H-aro). ^{13}C NMR ($CDCl_3$), δ : 31.77 (C-6); 40.83 (OCH_3); 52.90, 52.93 (2 OCH_3); 55.19 (C-7); 69.48 (C-5); 72.62 (CH_2Ph); 73.28 (CH_2Ph); 75.06 (C-2); 75.60 (CH_2Ph); 79.10 (C-4); 80.51 (C-3); 99.57 (C-1); 128.00-128.75 (15CH-aro); 138.66-138.84 ($3C^{IV}$ -aro); 170.00, 170.28 (2CO). MS ESI⁺, m/z : 601.28 [$M+Na$]⁺.

4.9. (Methyl 2,3,4-tri-*O*-benzyl-6,7-dideoxy-7-carboxy- α -D-manno-octopyranosid)uronic acid **8**

To a cooled (0 °C) solution of 4 N NaOH (1,3 mL) was added dropwise a solution of **7** (584 mg, 1.01 mmol) in THF/water (4/6 v/v, 5 mL). The mixture was sonicated at room temperature in an ultrasonic bath. After 35 min, the reaction was complete, as revealed by TLC. The mixture was acidified with a solution of 5 N HCl until pH 4.0 and then, extracted several times with ethyl acetate. The organic layer was washed with brine, dried (Na_2SO_4) and concentrated. The residue was purified by silica gel column chromatography (light petroleum/AcOEt 95/5 v/v) affording malonic acid **8** (528 mg, 95%) as a white powder. R_f 0.52 (AcOEt/MeOH 9/1). $[\alpha]_D^{20} +30.5$ (c 1.13 / $CHCl_3$). 1H NMR ($CDCl_3$), δ : 2.01 (m, 1H, H-6'); 2.49 (t, 1H, $J_{6-6'} = 14.0$ Hz, $J_{6-7} = 10.7$ Hz, H-6); 3.16 (s, 3H, OCH_3); 3.54 (t, 1H, $J_{5-4} = J_{5-6'} = 9.5$ Hz, H-5); 3.65-3.70 (m, 1H, H-7); 3.62 (t, 1H, $J_{4-3} = 9.5$ Hz, H-4); 3.66 (dd, 1H, $J_{2-1} = 1.5$ Hz, $J_{2-3} = 2.1$ Hz, H-2); 3.77 (dd, 1H, H-3); 4.49 (s, 2H, CH_2Ph); 4.55 (d, 1H, H-1); 4.58 (d, 1H, $J_{a-b} = 10.9$ Hz, CH_2Ph); 4.61 (d, 1H, $J_{a'-b'} = 12.3$ Hz, CH_2Ph); 4.67 (d, 1H, CH_2Ph); 4.86 (d, 1H, CH_2Ph); 7.09-7.27 (m, 15H, 15H-aro); 10.69 (br s, 2OH). ^{13}C NMR ($CDCl_3$), δ : 31.42 (C-6); 48.78 (OCH_3); 55.54 (C-7); 69.38 (C-5); 72.71-73.32 (2 CH_2Ph); 75.07 (C-2); 75.84 (CH_2Ph); 79.10 (C-4); 80.36 (C-3); 99.52 (C-1); 128.14-129.06 (15CH-aro); 138.46-138.76 ($3C^{IV}$ -aro); 174.59, 174.91 (2CO). MS ESI⁻, m/z : 549.14 [$M-H$]⁻.

4.10. Sodium (Methyl 6,7-dideoxy-7-carboxy- α -D-manno-octopyranosid)uronate **9**

A suspension of **8** (512 mg, 0.93 mmol) and Pd/C (10%, 200 mg) in EtOH/AcOEt (7/3 v/v) (20 mL) was vigorously stirred under an H_2 atmosphere for 4 h. The reaction was filtered through a Celite pad, and concentrated under reduced pressure. To the residue dissolved in water (50 mL) was added the cation exchange resin in the Na^+ form. After 2 h, the resin was filtered off and washed several times with water. The aqueous phase was lyophilized affording

9 (292 mg, 97%) as a white powder. R_f 0.28 (NH₄OH/H₂O/iPrOH 1/1/8). $[\alpha]_D^{20} +45.78$ (c 1.35 / H₂O). ¹H NMR (D₂O), δ : 1.90-1.96 (m, 1H, H-6'); 2.38-2.42 (m, 1H, H-6); 3.26 (s, 3H, OCH₃); 3.40 (t, 1H, $J_{4-3} = J_{4-5} = 9.1$ Hz, H-4); 3.44-3.48 (m, 2H, H-5, H-7); 3.61 (dd, 1H, $J_{3-2} = 3.4$ Hz, H-3); 3.82 (dd, 1H, $J_{2-1} = 1.5$ Hz, H-2); 4.61 (d, 1H, H-1). ¹³C NMR (D₂O), δ : 30.94 (C-6) ; 52.94 (OCH₃); 54.97 (C-7); 69.87, 70.22, 70.37, 70.69 (C-2,3,4,5); 100.84 (C-1); 174.71, 175.07 (2CO). MS ESI⁻, m/z : 279.19 [M-2Na+H]⁻.

4.11. Purification of the M6P/IGF2R

M6P/IGF2R was purified on a phosphomannan-sepharose affinity column, according to the method described by Brouillet¹⁹ *et al.*. Fetal calf serum (FCS) (200 mL) diluted in buffer A (200 mL) was passed over the PMP-affinity column. The column was washed with buffer A (40 mL) to remove unbound protein. Then the M6P/IGF2R was specifically eluted with 5mM mannose 6-phosphate. The different fractions were analysed by SDS-polyacrylamide gel electrophoresis (PAGE) (12% acrylamide) and protein (270 kDa) was detected by Coomassie blue staining. 672 μ g of M6P/IGF2R were recovered from 200 mL of FCS serum.

4.12. Biotinylation of the M6P/IGF2R

N-Hydroxysuccinimid biotin in dimethyl sulfoxide (10 mg.mL⁻¹) and the M6P/IGF2R (1mg.mL⁻¹) in PBS were mixed in a ratio which resulted in 110 μ g of ester per mg of receptor. The mixture was incubated end over end for 7 h at room temperature. To stop the reaction, ammonium chloride 2 M was added and stirring was kept for 10 min. Then the receptor was dialysed against PBS to remove excess of biotin. The PBS was changed to Buffer B before use in the binding assay.²⁰

4.13. Binding assay for mannose 6-phosphate analogues.

Phosphomannan core fragment (*i. e.* PMP functionalized with β -(*p*-aminophenyl)ethylamine) (200 μ L well, 200 μ g.mL⁻¹ in Carbonate Buffer) was adsorbed to microtiter wells of an ELISA plate (96 wells) overnight at 4 °C. Then the wells were saturated for 1 h at room temperature with 1% gelatine (Type A from Porcine Skin) in PBS (400 μ L) and washed 5 times with washing buffer (400 μ L). The analogues (10⁻³ M to 10⁻⁷ M concentration) and M6P/IGF2Rb (2.5 μ g.mL⁻¹), diluted in Buffer B + 2 mg.mL⁻¹ gelatine, were incubated 20 min. Then these mixtures (200 μ L) were placed in each well for 2 h at room temperature.

After 3 washes, the wells were incubated for 1 h at room temperature with 3×10^{-8} M streptavidin peroxidase. After washing, OPD solution was added (0.4 mg mL^{-1}) and the absorbance was measured after 15 min at 450 nm.

4.14. Serum stability and cellular cytotoxicity assays

The analogue stability was measured at 37°C after incubation for various time periods in human serum (75%, v/v). The binding affinity of the analogues for M6P/IGF2R was then tested using the assay already described.

The cytotoxicity of the analogues was estimated in human breast-cancer cell lines MDA-MB-231 and MCF7. MDA-MB-231 and MCF7 were maintained in Dulbecco's modified Eagle's medium (DMEM) and in F12/DMEM respectively, with 10% fetal calf serum and $5 \mu\text{g mL}^{-1}$ gentamycin in an atmosphere of 5% CO_2 . For each experiment, 5000 cells were plated into 24-well plate for 24 h and then grown for 4 days with cultured media containing various concentrations in M6P or its analogs (10^{-4} M to 10^{-6} M). The cell number was evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma) assay. Briefly, 500 μL of a MTT solution (1 mg mL^{-1} in PBS) was added per well and the mixture was allowed to stand for 4 h at 37°C . Then the MTT solution was removed and the formazan crystals were dissolved in DMSO/EtOH. The concentration of formazan was then evaluated using a multiplate reader spectrophotometer (Biorad 680) at 540 nm. Each data point resulted from triplicates.

References and notes

1. Stein, M.; Zijderhand-Bleekemolen, J.E.; Geuze, H.; Hasilik, A.; von Figura, K. *EMBO J* **1987**, *6*, 2677-2681.
2. Oka, Y.; Rozek, L.M.; Czech, M.P. *J. Biol. Chem.* **1985**, *260*, 9435-9442.
3. Kang, J.X.; Li, Y. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 13671-13676.
4. Wowk, M.E.; Trapani, J.A. *Microbes and Infection* **2004**, *6*, 752-758.
5. Dennis, P.A.; Rifkin, D.B. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 580-584.
6. O'Gorman, D.B.; Weiss, J.; Hettiaratchi, A.; Firth, S.M.; Scott, C.D. *Endocrinology* **2002**, *143*, 4287-4294.
7. Osipo, C.; Dorman, S.; Frankfater, A. *Exp. Cell Res.* **2001**, *264*, 388-396.
8. Tong, P.Y.; Gregory, W.; Kornfeld, S. *J. Biol. Chem.* **1989**, *264*, 7962-7969.
9. Hoflack, B.; Fujimoto, K.; Kornfeld, S. *J. Biol. Chem.* **1987**, *262*, 123-129.
10. Sleat, D.E.; Lobel, P. *J. Biol. Chem.* **1997**, *272*, 731-738.
11. Gabel, C.A.; Costello, C.E.; Reinhold, V.N.; Kurz, L.; Kornfeld, S. *J. Biol. Chem.* **1984**, *259*, 13762-13769.
12. Freeze, H.H. *Arch. Biochem. Biophys.* **1985**, *243*, 690-693.
13. Tong, P.Y.; Kornfeld, S. *J. Biol. Chem.* **1989**, *264*, 7970-7975.
14. Vidal, S.; Garcia, M.; Montero, J.-L.; Morère, A. *Bioorg. Med. Chem.* **2002**, *10*, 4051-4056.
15. Mahrwald, R.; Theil, F.; Schick, H.; Schwarz, S.; Palme, H.-J.; Weber, G. *J. Prakt. Chem.* **1986**, *328*, 777-783.
16. Vidal, S.; Vidal, S.; Morère, A.; Montero, J.-L. *Phosphorus, Sulfur and Silicon* **2000**, *158*, 125-139.
17. Borén, H. B.; Eklind, K.; Garegg, P. J.; Lindberg, B.; Pilotti, A. *Acta Chem. Scand.* **1972**, *26*, 4143-4146.
18. Vidal, S.; Montero, J.-L.; Leydet, A.; Morère, A. *Phosphorus, Sulfur and Silicon* **2002**, *177*, 2363-2377.
19. Brouillet, J.-P.; Dufour, F.; Lemamy, G.; Garcia, M.; Schlup, N.; Grenier, J.; Mani, J.-C.; Rochefort, H. *Cancer* **1997**, *79*, 2132-2136.
20. Christensen, M.K.; Meldal, M.; Bock, K.; Cordes, H.; Mouritsen, S.; Elsner, H. *J. Chem. Soc., Perkin Trans 1* **1994**, 1299-1310.
21. Berkowitz, D. B.; Maiti, G.; Charette, B. D.; Dreis, C. D.; MacDonald, R. G. *Org. Lett.* **2004**, *6*, 4921-4924.
22. Ferguson, M. W. J.; McNeight, D. L. PCT Int. Appl. WO 97 05, 883, 1997.
23. Perrin, D. D.; Amarego, W. L. F. *Purification of Laboratory Chemicals*, 3rd ed.; Pergamon Press: New York, 1988.
24. Slodki, M. E.; Ward, R. M.; Boundy, J. A. *Biochim. Biophys. Acta* **1973**, *304*, 449-456.